Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.
about
Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancerPhase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.Factors favouring long-term survival following recurrence in ovarian cancer.Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancerUpdates on drug discovery in ovarian cancer.Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.An overview of early investigational therapies for chemoresistant ovarian cancer.Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer.Hypoxia-regulated gene network in drug resistance and cancer progression.
P2860
Q26795742-C614817E-B1CD-46B9-B2BD-6EB9757060CCQ28648402-6DF7600B-0AFB-4BD0-A27E-8B6C58ED6959Q33416097-99241284-A2A2-4B7C-8258-59F05E48E3D1Q33857691-349E3590-FD2D-4935-A992-4D2735FAECE0Q34538416-F79CE9E3-2B84-40AD-86FE-83FB081E92E9Q35675340-D6DA80F3-699A-4BD8-B00F-F8CDC04E9B0FQ35805489-3214810D-B7EF-4A17-8BD7-58C370611A3FQ36929772-68EB654F-B965-4CB0-A290-DAE15D601910Q37706198-91F8D06F-6773-4DEE-863E-C245A5672A06Q38180311-36160D10-A6EE-4139-9631-1CC943BE19AFQ38553247-83D1127C-F7F6-464B-8DD1-4E70E5844974Q38718464-EAA510C8-D28B-4D7B-B48A-E9E9AEB3331CQ47096976-AFF1DBAB-08B6-45D0-ADFF-BCE5909749A8Q48172134-4658F823-60E1-465A-93D6-21CD55758504Q53724500-9A29052E-3E9E-4CED-A3C7-6AB9347C78FBQ54354000-9AB67645-15D9-44E3-BDFB-41FDCBC9DEDF
P2860
Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Randomized multicenter phase I ...... ory epithelial ovarian cancer.
@ast
Randomized multicenter phase I ...... ory epithelial ovarian cancer.
@en
type
label
Randomized multicenter phase I ...... ory epithelial ovarian cancer.
@ast
Randomized multicenter phase I ...... ory epithelial ovarian cancer.
@en
prefLabel
Randomized multicenter phase I ...... ory epithelial ovarian cancer.
@ast
Randomized multicenter phase I ...... ory epithelial ovarian cancer.
@en
P2093
P2860
P921
P356
P1476
Randomized multicenter phase I ...... ory epithelial ovarian cancer.
@en
P2093
Abraham C F Leung
Agustin Garcia
Carol Zhao
Charles Pippitt
Chris Poole
Christine Gennigens
Daniel Spitz
Emad N Ibrahim
Gordon Rustin
Graham Dark
P2860
P304
P356
10.1200/JCO.2012.45.1278
P407
P577
2013-09-30T00:00:00Z